AbbVie Inc. (NYSE:ABBV) Plans Quarterly Dividend of $1.73

AbbVie Inc. (NYSE:ABBV) announced a quarterly dividend on Thursday, September 10th. Stockholders of record on Thursday, October 15th will be given a dividend of 1.73 per share on Monday, November 16th. This represents a c) annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Thursday, October 15th.

AbbVie has raised its dividend payment by an average of 0.1%annually over the last three years and has increased its dividend annually for the last 53 consecutive years. AbbVie has a dividend payout ratio of 49.5% meaning its dividend is sufficiently covered by earnings. Research analysts expect AbbVie to earn $16.15 per share next year, which means the company should continue to be able to cover its $6.92 annual dividend with an expected future payout ratio of 42.8%.

AbbVie Stock Up 1.6%

Shares of NYSE:ABBV opened at $255.00 on Friday. The business’s 50 day moving average is $254.54 and its 200 day moving average is $230.76. The stock has a market cap of $450.52 billion, a P/E ratio of 72.03, a price-to-earnings-growth ratio of 1.13 and a beta of 0.29. AbbVie has a 52-week low of $190.75 and a 52-week high of $267.47.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The business had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. During the same period in the prior year, the business earned $2.97 EPS. The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, sell-side analysts anticipate that AbbVie will post 14.05 EPS for the current fiscal year.

About AbbVie

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott’s diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.

AbbVie’s immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.